PRTN3 and tenosynovitis: Whereas some of the here used monoclonal ACPA have previously shown to induce symptoms such as arthralgia, bone loss or tenosynovitis that often precede onset of RA, the present demonstration of a dominant anti-inflammatory effect by certain monoclonal and polyclonal ACPA calls for a re-evaluation of the proposed role of these antibodies in RA.